Primary FDA-Approved Use
Darolutamide (brand name Nubeqa) treats non-metastatic castration-resistant prostate cancer (nmCRPC) in adults. It is used alongside continued androgen deprivation therapy (ADT) to delay metastasis and reduce associated risks.[1]
How It Works in Prostate Cancer
Darolutamide is an androgen receptor inhibitor that blocks androgen signaling, slowing cancer growth in hormone-sensitive tumors. Clinical trials like ARAMIS showed it extends metastasis-free survival by about 22 months compared to placebo when added to ADT.[1][2]
Off-Label or Investigational Uses
Darolutamide is studied for metastatic hormone-sensitive prostate cancer (mHSPC) and other stages, often combined with docetaxel or ADT. Phase 3 trials like ARASENS support these combinations, but FDA approval remains limited to nmCRPC.[2][3]
Comparison to Similar Drugs
Unlike enzalutamide or apalutamide, darolutamide has lower blood-brain barrier penetration, potentially reducing risks like seizures or cognitive effects. All target androgen receptors for prostate cancer but differ in trial endpoints and side effect profiles.[1][4]
Common Side Effects Patients Report
Fatigue, pain in extremities, rash, and falls occur frequently. It raises fracture risk, prompting bone health monitoring. Fewer central nervous system effects than rivals make it preferable for some patients.[1][2]
[1]: FDA Label for Nubeqa
[2]: NEJM: ARAMIS Trial
[3]: ClinicalTrials.gov: Darolutamide Studies
[4]: DrugPatentWatch: Darolutamide Patent Landscape